🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

I feel more optimism now than ever before. As I explained to Dave Briggs, aging is the leading risk factor for #Alzheimers which is why treatments informed by the #BiologyofAging are critical. ADDF support will help these treatments cross the finish line yhoo.it/3DwHGZM

Amidst news on anti-#amyloid therapies, hope continues to lie in the next generation of #Alzheimers drugs that explore other targets based on the biology of aging. Many of these drugs are in development, with 75% of drugs in the pipeline now targeting non-amyloid pathways.

Clearing of #amyloid plaques resulting from drugs like #lecanemab has shown modest benefit that by itself may not make a significant difference to patients, reported Dominique Mosbergen of The Wall Street Journal: on.wsj.com/3Ev1uNy This is why ADDF supports combination therapies as the path forward.

While data from #gantenerumab is disappointing for the many patients living with #Alzheimers, the #ADDF remains optimistic about the state of Alzheimer's drug development research. Today's diverse pipeline shows 75% of drugs explore novel targets based on the biology of aging.

Last week at the #MIHealthSummit, the #ADDF's Howard Fillit, MD joined other thought leaders for a panel on ARPA-H, sharing innovative and creative solutions to large-scale #health challenges facing society, including #Alzheimers.

Today's approval of #lecanemab is an encouraging step toward having the multiple drugs we will need to combine in personalized treatments and address each patient's unique #Alzheimers pathology in order to provide meaningful relief. bit.ly/3XeTUg2

Today marks a milestone moment for the #Alzheimers field with the approval of lecanemab, but there remains a pressing need for a new generation of drugs that target a whole host of underlying factors based on our understanding of the biology of aging.

As we enter the, "golden age of drug discovery," as stated in Gina Kolata's article, it's important to identify new #biomarkers to reduce the costs of developing drugs for diseases, like #Alzheimers, which enable us to run more rigorous & efficient trials nyti.ms/40CSOxr

I’m excited to share a new $200M gift from the Lauder family will fuel Alzheimer's Drug Discovery Foundation to advance the next generation of drugs based on the #biologyofaging, allowing us to explore the full potential of the pipeline and move the most promising research forward: bit.ly/3G3gNNG

Today's endorsement of Leqembi from the FDA Advisory Committee is encouraging news, but our goal is to develop multiple novel therapies based on the biology of aging to be used in combination with anti-amyloid therapies to stop Alzheimer's in its tracks

Aging is the leading risk factor for #Alzheimers, so we must leverage #CombinationTherapy to target the many different pathologies based on the biology of aging & #comorbidities that lead to its onset. The truth is, no single drug will effectively treat and/or cure the disease.

Today's #FDA approval of #leqembi marked a momentous day in the #Alzheimers field. Howard Fillit, MD notes how this approval will serve as a catalyst for driving further developments and investments in the Alzheimer’s drug pipeline based on the biology of aging: bit.ly/3PLD4oB.

Today at #AAIC23, Eli Lilly and Company announced the anti-amyloid #donanemab slows #CognitiveDecline by 35%. Howard Fillit, MD notes this serves as further validation that anti-amyloid therapies will be the first class of several classes of drugs to treat #Alzheimers: bit.ly/3rEdNmc

The ADDF is thrilled to announce a new, one-of-a-kind partnership with FINGERS Brain Health Institute around #PrecisionPrevention, which aims to uncover new ways to #prevent & treat #Alzheimers by combining #lifestyle & #therapeutic interventions: bit.ly/3LMGtky

Great opportunity to advance biomarker research for Alzheimer's disease!

Brilliant panel on the Biology of Aging at #ADPD2024 lead by ⁦Niranjan Bose⁩ featuring ⁦⁦🟧 Susan Kohlhaas 🟧⁩ ⁦Howard Fillit, MD⁩ and our good friends from Dementia Discovery Fund and EQT Life Sciences

Inspiring start of Day 3 at #ADPD2024 with Howard Fillit, MD 🤩 “We need to foster collaboration between the #geroscience and #neuroscience community to advance disease treatment. The ultimate goal is to adopt a precision medicine approach based on each patient's unique biomarkers.”

Today #ADDF Co-Founder and Chief Science Officer Howard Fillit, MD delivered a poignant plenary lecture at #ADPD2024 on why the biology of aging framework will guide the next generation of #Alzheimers drugs as we move towards combination therapy and #precisionmedicine. AD/PD - Advances in Science & Therapy

At #CTAD24, roundtable on #combinationtherapy highlights new era of #Alzheimers, which is moving closer to a #precisionmedicine approach. Combination trials will define the next phase of therapies, helping us better understand which biological process contribute to the disease

ADDF's Inaugural Scientific Summit united top scientists in #Alzheimers. Daniel Skovronsky of Eli Lilly and Company received the Melvin R. Goodes Prize, the Nobel Prize of Alzheimer's, & featured a panel w/Niranjan Bose & an inspiring address from Dr. Sanjay Gupta bit.ly/43qaz6N